Clinical utility and safety of MultiHance in magnetic resonance imaging of liver cancer: results of multicenter studies in Europe and the USA.
MultiHance (gadobenate dimeglumine; Gd-BOPTA, Bracco SpA, Milano, Italy) is a novel gadolinium-based contrast agent which has recently been made commercially available in Europe for magnetic resonance imaging of the liver. It combines the properties of a conventional extracellular fluid contrast agent with those of a liver-specific agent and has been shown in numerous clinical trials to improve the impact of magnetic resonance imaging for both the detection and characterization of focal liver masses. The present article briefly summarizes the safety and efficacy results of Phase I, II and III clinical studies carried out in almost 800 patient and non-patient volunteers in both Europe and the USA.
Hamm
B
B
Department of Radiology, Charité, Humboldt-Universität zu Berlin, Germany.
Kirchin
M
M
Pirovano
G
G
Spinazzi
A
A
D006528:Carcinoma, Hepatocellular / Q000175:diagnosis*; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000009:adverse effects; D005060:Europe; D005682:Gadolinium / Q000009:adverse effects; D006801:Humans; D008099:Liver / Q000473:pathology*; D008113:Liver Neoplasms / Q000175:diagnosis*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008536:Meglumine / Q000009:adverse effects / Q000031:analogs & derivatives*; D015337:Multicenter Studies as Topic; D009942:Organometallic Compounds / Q000009:adverse effects; D012449:Safety; D014481:United States
D003287:Contrast Media; D009942:Organometallic Compounds; C064572:gadobenic acid; D008536:Meglumine; D005682:Gadolinium